Scarica l'app Stockscreener
2.2676
2.61%
0.0576
Senti Biosciences Inc Borsa (SNTI) Ultime notizie
Senti Biosciences Inc (SNTI) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Senti Bio Receives US FDA Orphan Drug Designation for Potential Blood Cancer Treatment - MarketScreener
Senti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug Designation - Nasdaq
FDA grants orphan drug designation to Senti Bio’s AML treatment - Investing.com
FDA Backs Senti Bio Revolutionary Cancer Drug as 60% of AML Patients Face Critical Outcomes - Stock Titan
Senti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan Capital - Defense World
Senti Biosciences (SNTI) Rating and Price Target Updated by Chardan Capital | SNTI Stock News - GuruFocus
Senti Biosciences Announces New Employment Inducement Grants - The Manila Times
Gene Circuit Pioneer Senti Bio Grants $310K in Stock Options to Expand Next-Gen Therapy Team - Stock Titan
Laidlaw Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc.SNTI - WV News
SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. | SNTI Stock News - GuruFocus
Laidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy Recommendation - Nasdaq
SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. - GuruFocus
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC - The Manila Times
Exclusive: Senti Bio Leaders Reveal Next-Gen Cell Therapy Vision in Chardan Fireside Discussion - Stock Titan
Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target - GuruFocus
Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target | SNTI Stock News - GuruFocus
Laidlaw initiates coverage on Senti Biosciences stock with buy rating By Investing.com - Investing.com Nigeria
Laidlaw initiates coverage on Senti Biosciences stock with buy rating - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amerant Bancorp Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti ... - Bluefield Daily Telegraph
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc - ACCESS Newswire
Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise - insights.citeline.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc.GMED - PR Newswire
Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc - ACCESS Newswire
Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - The Manila Times
Senti Bio CEO Reveals Next-Gen Gene Circuit Platform: Live Webull Biotech Investment Presentation Coming May 29 - Stock Titan
Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Develo - GuruFocus
Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Development | SNTI Stock News - GuruFocus
Senti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell Therapy - Nasdaq
Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 - Yahoo Finance
SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com
Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire
Senti Biosciences advances AML treatment with SENTI-202 trial By Investing.com - Investing.com Nigeria
Senti Biosciences advances AML treatment with SENTI-202 trial - Investing.com
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 - The Manila Times
Renaissance Technologies LLC Makes New $181,000 Investment in Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development - The Manila Times
Senti Biosciences Reports Positive Phase 1 Results for SENTI-202 in Acute Myeloid Leukemia Treatment - Nasdaq
Senti Bio Phase 1 Trial Shows 57% Complete Remission Rate in AML Treatment | SNTI Stock News - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI - FinancialContent
Senti Biosciences’ (SNTI) Buy Rating Reiterated at Chardan Capital - Defense World
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):